Stocktoria
GILEAD SCIENCES, INC. GILD
GILEAD SCIENCES, INC. (GILD) earns a Piotroski F-score of 7/9 (strong financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 2.52% (safety: moderate). FY2025 revenue was $29.4B at a 28.9% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.48 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-08-05 | RBC Capital | Sector Perform (main) |
| 2026-08-05 | Cantor Fitzgerald | Overweight (reit) |
| 2026-08-05 | Needham | Buy (reit) |
| 2026-07-29 | Barclays | Equal-Weight (main) |
| 2026-07-27 | Morgan Stanley | Overweight (main) |
| 2026-07-21 | Leerink Partners | Market Perform (down) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 7/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.111 |
| Retained earnings / assets | 0.233 |
| EBIT / assets | 0.17 |
| Equity / liabilities | 0.625 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| GILD | GILEAD SCIENCES, INC. | 7/9 | 3.28 | 18.7 | +2.4% |
| AMGN | AMGEN INC | 6/9 | 0.14 | 25.1 | +10% |
| BIIB | BIOGEN INC. | 4/9 | — | 24.7 | +2.2% |
| NBIX | NEUROCRINE BIOSCIENCES INC | 5/9 | 6.21 | 35.4 | +21.4% |
| EXEL | EXELIXIS, INC. | 6/9 | 7.69 | 17.6 | +7% |
| QGEN | QIAGEN N.V. | 7/9 | 5.06 | 19.1 | +5.7% |
| HALO | HALOZYME THERAPEUTICS, INC. | 5/9 | 3.02 | 28.1 | +37.6% |
About GILEAD SCIENCES, INC.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
FAQ
Is GILD financially healthy?
GILEAD SCIENCES, INC.'s Piotroski F-score is 7/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does GILD pay a dividend, and is it safe?
Yes. GILEAD SCIENCES, INC. pays a dividend yielding about 2.52% with a 47.0% payout ratio, rated “moderate” for safety.
How profitable is GILD?
In FY2025, GILEAD SCIENCES, INC. had a net margin of 28.9% and a return on equity of 37.5%.
Is GILD overvalued or undervalued?
GILEAD SCIENCES, INC. trades at about 20.0× trailing earnings — near its 10-year norm (10-year range 7.3×–656.0×, median 20.9×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for GILD?
The average Wall-Street price target for GILEAD SCIENCES, INC. is $157.41, about 15.9% above the recent price, from 27 analysts (consensus: buy).
Is GILD a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on GILEAD SCIENCES, INC.: a Piotroski F-score of 7/9, an Altman Z″ in the safe zone, a P/E of about 18.7×, a dividend yield of 2.52%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.